Mechanistic role of CXCL5 in cardiovascular disease, diabetes mellitus, and kidney disease

被引:8
|
作者
Chen, Ching [1 ]
Chang, Ting-Ting [1 ,2 ]
Chen, Jaw-Wen [1 ,3 ,4 ,5 ,6 ,7 ,8 ]
机构
[1] Natl Yang Ming Chiao Tung Univ, Dept & Inst Pharmacol, Sch Med, Taipei, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Biomed Ind PhD Program, Taipei, Taiwan
[3] Taipei Med Univ Hosp, Div Cardiol, Dept Med, Taipei, Taiwan
[4] Taipei Med Univ Hosp, Dept Res, Taipei, Taiwan
[5] Taipei Med Univ Hosp, Cardiovasc Res Ctr, Taipei, Taiwan
[6] Taipei Med Univ, Taipei, Taiwan
[7] Natl Yang Ming Chiao Tung Univ, Cardiovasc Res Ctr, Taipei, Taiwan
[8] Taipei Med Univ Hosp, Dept Res, Taipei, Taiwan
关键词
Chemokine; Cardiovascular disease; Diabetes mellitus; Kidney disease; CXCL5; CHEMOKINE RECEPTORS; PEPTIDE ENA-78; NEUTROPHIL RECRUITMENT; LIGAND; 5; CELLS; EXPRESSION; CYTOKINES; OBESITY; INFLAMMATION; HOMEOSTASIS;
D O I
10.1016/j.lfs.2023.122018
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Chemokines, by modulating inflammation process, could contribute to the development of cardiovascular dis-ease, diabetes mellitus (DM), and kidney disease. Chemokine CXC motif ligand 5 (CXCL5) is one of the inducible chemokines that may be involved in various inflammatory diseases. Given the bidirectional promiscuity char-acteristics of the chemokine system, the mechanistic roles of CXCL5 should be further explored in each specific disease. In this article, we sought to review the recent evidence on the differential effects of CXCL5 and their potential mechanisms in cardiovascular disease, DM, and renal disease individually. Future study is still required to verify if CXCL5 could be a novel therapeutic target in these diseases.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease
    Ravi, Saranya
    Schuck, Robert N.
    Hilliard, Eleanor
    Lee, Craig R.
    Dai, Xuming
    Lenhart, Kaitlin
    Willis, Monte S.
    Jensen, Brian C.
    Stouffer, George A.
    Patterson, Cam
    Schisler, Jonathan C.
    AMERICAN JOURNAL OF PATHOLOGY, 2017, 187 (12) : 2895 - 2911
  • [2] CXCL5 suppression recovers neovascularization and accelerates wound healing in diabetes mellitus
    Chen, Ching
    Lin, Liang-Yu
    Chen, Jaw-Wen
    Chang, Ting-Ting
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [3] CXCL5 Inhibition Recovers Neovascularization in Diabetes Mellitus
    Chang, Ting-Ting
    Chen, Ching
    Lin, Liang-Yu
    Chen, Jaw-Wen
    CIRCULATION, 2023, 148
  • [4] CXCL5 drives obesity to diabetes, and further
    Chavey, Carine
    Fajas, Lluis
    AGING-US, 2009, 1 (07): : 674 - 677
  • [5] CXCL5 is associated with the increased risk of coronary artery disease
    Wang, Xiao-Zeng
    Liu, Li-Wen
    Du, Xiao-Mo
    Gu, Ruo-Xi
    Sun, Zhi-Jun
    CORONARY ARTERY DISEASE, 2015, 26 (07) : 612 - 619
  • [6] CHRONIC KIDNEY DISEASE, DIABETES MELLITUS AND CARDIOVASCULAR DISEASE: RISKS AND COMMONALITIES
    Suckling, Rebecca
    Gallagher, Hugh
    JOURNAL OF RENAL CARE, 2012, 38 : 4 - 11
  • [7] CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease
    Chang, Ting-Ting
    Chen, Ching
    Chen, Jaw-Wen
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [8] CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease
    Ting-Ting Chang
    Ching Chen
    Jaw-Wen Chen
    Cardiovascular Diabetology, 21
  • [9] Pathophysiology of cardiovascular disease in diabetes mellitus
    Rodriguez-Araujo, Gerardo
    Nakagami, Hironori
    CARDIOVASCULAR ENDOCRINOLOGY & METABOLISM, 2018, 7 (01) : 4 - 9
  • [10] CXCL5 suppression recovers neovascularization and accelerates wound healing in diabetes mellitus
    Ching Chen
    Liang-Yu Lin
    Jaw-Wen Chen
    Ting-Ting Chang
    Cardiovascular Diabetology, 22